Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals (ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $23.99
  • 50 Day Moving Average: $21.86
  • 200 Day Moving Average: $14.14
  • 52-Week Range: $4.67 - $23.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -57.12
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.16
Profitability:
  • Net Margins: -16.99%
  • Return on Assets: -5.12%
Debt:
  • Debt-to-Equity Ratio: -11.28%
  • Current Ratio: 3.17%
  • Quick Ratio: 3.15%

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $16.54 (31.05% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$24.00N/AView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2017Barclays PLCUpgradeUnderweight -> Equal Weight$9.00 -> $24.00N/AView Rating Details
1/10/2017Jefferies Group LLCDowngradeBuy -> Hold$11.00 -> $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016JPMorgan Chase & Co.DowngradeNeutral -> Underweight$9.97 -> $7.00N/AView Rating Details
6/20/2016Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$7.00 -> $5.00N/AView Rating Details
6/5/2015HC WainwrightReiterated RatingBuyN/AView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00N/AView Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyN/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Earnings History by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017        
11/7/2016Q316($0.19)($0.12)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20164($0.21)($0.17)($0.19)
Q4 20164($0.19)($0.16)($0.18)
Q1 20172($0.24)($0.21)($0.23)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.22)($0.22)($0.22)
Q4 20172($0.57)($0.21)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ariad Pharmaceuticals (NASDAQ:ARIA)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
Source:
DateHeadline
thestreet.com logoAfter Soaring to $150, Can Incyte Stir Up More Upside? (NASDAQ:ARIA)
www.thestreet.com - March 15 at 3:49 PM
nasdaq.com logoTrump???s Immigration Plans an Overhang on Biotech ETFs? (NASDAQ:ARIA)
www.nasdaq.com - March 2 at 3:51 PM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters (NASDAQ:ARIA)
www.reuters.com - February 18 at 3:34 PM
reuters.com logoBRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals (NASDAQ:ARIA)
www.reuters.com - February 17 at 6:32 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US (NASDAQ:ARIA)
www.prnewswire.com - February 16 at 8:41 PM
prnewswire.com logoMedinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US (NASDAQ:ARIA)
www.prnewswire.com - February 16 at 8:41 PM
streetinsider.com logoTakeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA) (NASDAQ:ARIA)
www.streetinsider.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o (NASDAQ:ARIA)
biz.yahoo.com - February 16 at 8:41 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. - Yahoo Finance (NASDAQ:ARIA)
finance.yahoo.com - February 16 at 3:40 PM
finance.yahoo.com logoTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)
au.finance.yahoo.com - February 16 at 3:40 PM
biz.yahoo.com logoARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ARIA)
us.rd.yahoo.com - February 8 at 8:53 PM
finance.yahoo.com logoARIAD Files for EU Approval of Lung Cancer Drug Brigatinib (NASDAQ:ARIA)
finance.yahoo.com - February 7 at 4:31 PM
investopedia.com logoAriad Submits Brigatinib Marketing Application (ARIA) (NASDAQ:ARIA)
www.investopedia.com - February 7 at 1:44 AM
rttnews.com logoARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA (NASDAQ:ARIA)
www.rttnews.com - February 7 at 1:44 AM
us.rd.yahoo.com logo7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA (NASDAQ:ARIA)
us.rd.yahoo.com - February 7 at 1:44 AM
us.rd.yahoo.com logoARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency (NASDAQ:ARIA)
us.rd.yahoo.com - February 7 at 1:44 AM

Social

Frequently Asked Questions for Ariad Pharmaceuticals (NASDAQ:ARIA)

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its quarterly earnings data on Thursday, July, 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The firm had revenue of $65.30 million for the quarter, compared to analysts' expectations of $60.64 million. Ariad Pharmaceuticals's revenue for the quarter was up 133.0% on a year-over-year basis. During the same period last year, the firm posted ($0.28) earnings per share.

When will Ariad Pharmaceuticals make its next earnings announcement?

Ariad Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?

10 analysts have issued 12-month target prices for Ariad Pharmaceuticals' stock. Their forecasts range from $7.00 to $24.00. On average, they expect Ariad Pharmaceuticals' share price to reach $16.54 in the next year.

Are investors shorting Ariad Pharmaceuticals?

Ariad Pharmaceuticals saw a decrease in short interest in the month of February. As of February 15th, there was short interest totalling 23,688,420 shares, a decrease of 6.5% from the January 31st total of 25,348,200 shares. Based on an average daily volume of 6,397,749 shares, the short-interest ratio is currently 3.7 days. Currently, 13.6% of the company's shares are sold short.

Who owns Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.33%), BlackRock, Inc (7.70%), Takeda Pharmaceutical Company Limited (6.80%), Sarissa Capital Management LP (6.62%), State Street Corp (4.05%) and Putnam Investments LLC (0.00%). Company insiders that own Ariad Pharmaceuticals stock include Athanese Lavidas, Daniel M Bollag, David L Berstein, Edward M Fitzgerald, Frank Haluska, Hugh M Cole, Maria E Cantor, Martin J Duvall, Massimo Radaelli, Paris Panayiotopoulos and Timothy P Clackson.

Who sold Ariad Pharmaceuticals stock? Who is selling Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management, Royce & Associates LP, Opaleye Management Inc., Guggenheim Capital LLC, Commerzbank Aktiengesellschaft FI, National Planning Corp and State Board of Administration of Florida Retirement System. Company insiders that have sold Ariad Pharmaceuticals stock in the last year include Athanese Lavidas, Daniel M Bollag, Hugh M Cole, Massimo Radaelli and Timothy P Clackson.

Who bought Ariad Pharmaceuticals stock? Who is buying Ariad Pharmaceuticals stock?

Ariad Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, FMR LLC, Norges Bank, Putnam Investments LLC, Two Sigma Investments LP, A.R.T. Advisors LLC, State Street Corp and Advisory Research Inc..

How do I buy Ariad Pharmaceuticals stock?

Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ariad Pharmaceuticals stock cost?

One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.

Ariad Pharmaceuticals (ARIA) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff